The first patient dosed in Australia with INNOGEN-B(02591) in a Phase II clinical trial for the treatment of obesity and overweight with exenatide alpha was completed.
Silver Noble Pharmaceuticals-B (02591) announces that on August 25, 2025, the company has completed the acquisition in Australia...
INNOGEN-B (02591) announces that on August 25, 2025, the company has dosed the first patient in Australia with IISupageglutide-alpha for the treatment of obesity and overweight in a phase II clinical trial. The company anticipates that approximately 200 participants will be enrolled in this clinical trial.
Related Articles
US Stock Market Move | "The most important stock on earth" NVIDIA Corporation (NVDA.US) is about to announce its second quarter earnings. The stock price rose nearly 1% in intraday trading.
US Stock Market Move | Chip stocks rose slightly, with AMD (AMD.US) up more than 1.3%.
US Stock Market Move | Femasys (FEMY.US) stock price plummets 37%, hitting a new low for the year.
US Stock Market Move | "The most important stock on earth" NVIDIA Corporation (NVDA.US) is about to announce its second quarter earnings. The stock price rose nearly 1% in intraday trading.
US Stock Market Move | Chip stocks rose slightly, with AMD (AMD.US) up more than 1.3%.
US Stock Market Move | Femasys (FEMY.US) stock price plummets 37%, hitting a new low for the year.
RECOMMEND
Analysts Respond to Trump’s Dismissal of Fed Governor Cook as a Further Assault on Central Bank Independence
26/08/2025
U.S. Proposes Including Copper, Silicon, Silver on 2025 Critical Minerals List Amid Supply Chain Concerns
26/08/2025
Trump Vows to Slash U.S. Drug Prices by Up to 1500%, Triggering Sell-Off in Pharma Stocks
26/08/2025
